EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib
- PMID: 15329413
- PMCID: PMC516528
- DOI: 10.1073/pnas.0405220101
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib
Abstract
Somatic mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) gene are reportedly associated with sensitivity of lung cancers to gefitinib (Iressa), kinase inhibitor. In-frame deletions occur in exon 19, whereas point mutations occur frequently in codon 858 (exon 21). We found from sequencing the EGFR TK domain that 7 of 10 gefitinib-sensitive tumors had similar types of alterations; no mutations were found in eight gefitinib-refractory tumors (P = 0.004). Five of seven tumors sensitive to erlotinib (Tarceva), a related kinase inhibitor for which the clinically relevant target is undocumented, had analogous somatic mutations, as opposed to none of 10 erlotinib-refractory tumors (P = 0.003). Because most mutation-positive tumors were adenocarcinomas from patients who smoked <100 cigarettes in a lifetime ("never smokers"), we screened EGFR exons 2-28 in 15 adenocarcinomas resected from untreated never smokers. Seven tumors had TK domain mutations, in contrast to 4 of 81 non-small cell lung cancers resected from untreated former or current smokers (P = 0.0001). Immunoblotting of lysates from cells transiently transfected with various EGFR constructs demonstrated that, compared to wild-type protein, an exon 19 deletion mutant induced diminished levels of phosphotyrosine, whereas the phosphorylation at tyrosine 1092 of an exon 21 point mutant was inhibited at 10-fold lower concentrations of drug. Collectively, these data show that adenocarcinomas from never smokers comprise a distinct subset of lung cancers, frequently containing mutations within the TK domain of EGFR that are associated with gefitinib and erlotinib sensitivity.
Figures
![Fig. 1.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/516528/bin/zpq0350458530001.gif)
![Fig. 2.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/516528/bin/zpq0350458530002.gif)
![Fig. 3.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/516528/bin/zpq0350458530003.gif)
![Fig. 4.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/516528/bin/zpq0350458530004.gif)
Similar articles
-
Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.J Thorac Oncol. 2014 Apr;9(4):506-11. doi: 10.1097/JTO.0000000000000095. J Thorac Oncol. 2014. PMID: 24736073
-
Mutation and polymorphism in the EGFR-TK domain associated with lung cancer.J Thorac Oncol. 2006 Sep;1(7):635-47. J Thorac Oncol. 2006. PMID: 17409930
-
Epidermal growth factor receptor mutations are associated with gefitinib sensitivity in non-small cell lung cancer in Japanese.Lung Cancer. 2006 Jan;51(1):71-7. doi: 10.1016/j.lungcan.2005.08.006. Epub 2005 Sep 29. Lung Cancer. 2006. PMID: 16198442
-
Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions.J Clin Oncol. 2005 Apr 10;23(11):2556-68. doi: 10.1200/JCO.2005.07.799. Epub 2005 Mar 14. J Clin Oncol. 2005. PMID: 15767641 Review.
-
[Translational research on lung cancer--EGFR gene mutation].Gan To Kagaku Ryoho. 2005 Jun;32(6):750-8. Gan To Kagaku Ryoho. 2005. PMID: 15984511 Review. Japanese.
Cited by
-
Osimertinib Resistance via Histologic Transformation From Non-small Cell Lung Carcinoma to Carcinosarcoma.Cureus. 2024 Apr 29;16(4):e59293. doi: 10.7759/cureus.59293. eCollection 2024 Apr. Cureus. 2024. PMID: 38813335 Free PMC article.
-
Efficacy of befotertinib in non-small cell lung cancer harboring uncommon compound EGFR mutations G719X and S768I: a case report.Front Oncol. 2024 Apr 4;14:1370666. doi: 10.3389/fonc.2024.1370666. eCollection 2024. Front Oncol. 2024. PMID: 38638860 Free PMC article.
-
Role of Insulin-like Growth Factor-1 Receptor in Tobacco Smoking-Associated Lung Cancer Development.Biomedicines. 2024 Mar 2;12(3):563. doi: 10.3390/biomedicines12030563. Biomedicines. 2024. PMID: 38540176 Free PMC article. Review.
-
Background and clinical significance of biomarker-based patient enrichment in non-small-cell lung cancer drug development.Sci Rep. 2024 Mar 26;14(1):7194. doi: 10.1038/s41598-024-57556-3. Sci Rep. 2024. PMID: 38531888 Free PMC article.
-
Uncovering the potentiality of quinazoline derivatives against Pseudomonas aeruginosa with antimicrobial synergy and SAR analysis.J Antibiot (Tokyo). 2024 Jun;77(6):365-381. doi: 10.1038/s41429-024-00717-3. Epub 2024 Mar 21. J Antibiot (Tokyo). 2024. PMID: 38514856
References
-
- Blume-Jensen, P. & Hunter, T. (2001) Nature 411, 355-365. - PubMed
-
- Moody, S. E., Sarkisian, C. J., Hahn, K. T., Gunther, E. J., Pickup, S., Dugan, K. D., Innocent, N., Cardiff, R. D., Schnall, M. D. & Chodosh, L. A. (2002) Cancer Cell 2, 451-461. - PubMed
-
- Huettner, C. S., Zhang, P., Van Etten, R. A. & Tenen, D. G. (2000) Nat. Genet. 24, 57-60. - PubMed
-
- Weinstein, I. (2002) Science 297, 63-64. - PubMed
-
- Druker, B. (2002) Trends Mol. Med. 8, S14-S18. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous